Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide.
Ontology highlight
ABSTRACT: Background: HIV pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine is effective when taken daily. Previously, we developed a urine assay capable of detecting the prodrug tenofovir (TFV) in patients taking tenofovir disoproxil fumarate (TDF)-based PrEP. However, tenofovir alafenamide (TAF) has replaced TDF due to its different safety profile for HIV treatment and was recently approved as PrEP. Given the need to ensure the aforementioned assay remains available for the purpose of objective adherence monitoring, it is critical to ensure its accuracy for detecting TFV in patients taking TAF. Methods: Blood and urine samples were collected from 3 cohorts of patients: (1) 10 participants living with HIV (PLWH) with suppressed virus on a TAF-based regimen, (2) 10 HIV-parti
SUBMITTER: Lalley-Chareczko L
PROVIDER: S-EPMC7096572 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
ACCESS DATA